CTRI/2023/01/048645招募中3 期
Multicenter, Randomized, Open-label, Comparative, Parallel Group study to assess the efficacy and safety of a fixed dose combination of Lupins Glycopyrronium plus Vilanterol dry powder inhaler versus fixed dose combination of Glycopyrronium plus Formoterol dry powder inhaler in patients with Chronic obstructive pulmonary disease
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 250
- 试验地点
- 12
- 主要终点
- •Change from baseline in trough FEV1
研究概览
简要总结
A Multi-center, Randomized,Open-label, Comparative, Parallel Group study to assess the efficacy and safety of a fixed dose combination ofLupin’s Glycopyrronium + Vilanteroldry powder inhaler versus fixed dose combination of Glycopyrronium + Formoterol dry powder inhalerin patients with Chronicobstructive pulmonary disease.
Approximately 14 weeks
Screening up to 10 days{including run-in period of atleast 7 days}
Treatment period: 12 weeks]
研究设计
- 研究类型
- Interventional
- 分配方式
- Computer generated randomization
- 盲法
- Open Label
入排标准
- 年龄范围
- 18.00 Year(s) 至 75.00 Year(s)（—）
- 性别
- All
入选标准
- •Male or female patients, aged ≥18 to ≤ 75 years at screening
- •Patients with a diagnosis of COPD (as defined by the GOLD Guidelines, 2021)
- •Post-bronchodilator FEV1 ≥30% and <80% of the predicted normal value and post-bronchodilator FEV1/FVC (forced vital capacity) ratio < 0.70
- •COPD treatment stable dose of maintenance monotherapy (LAMA, LABA or ICS), or stable dose of double maintenance therapy (LAMA/LABA or ICS/LABA), for one month prior to screening
- •Current or previous cigarette/beedi smokers with a history of cigarette/beedi smoking of at least 10 pack/years.
- •(Previous smokers are defined as those who have stopped smoking for at least 6 months prior to Screening Visit.).
排除标准
- •Subjects who will not meet any of the following criteria will be included in the trial:
- •Patients who are currently receiving dual drug treatment with LABA+LAMA
- •Known respiratory disorders other than COPD including, but not limited to the following: tuberculosis, alpha-1 antitrypsin deficiency, cystic fibrosis, asthma, active bronchiectasis, sarcoidosis, lung fibrosis, pulmonary hypertension, pulmonary edema, or interstitial lung disease
- •Evidence or history of other clinically significant cardiovascular disease or abnormality (such as, but not limited to, congestive heart failure, uncontrolled hypertension, uncontrolled coronary artery disease, myocardial infarction, arrhythmia, long QT syndrome, atrial fibrillation), renal, neurological, endocrine, immunological, psychiatric, hepatic, or hematological disease or abnormality which, in the opinion of the investigator, are clinically significant and would put the patient at risk through study participation, or would affect the study analyses if the disease exacerbates during the study
- •No significant abnormality that suggests chest disease other than COPD, on chest X-ray or computed tomography (CT) scan taken within six months before screening.
- •If there is no chest X-ray/CT scan is taken within six months prior to screening, a chest X-ray will be performed during screening to rule out any other significant abnormality.
- •History of paradoxical bronchospasm, narrow-angle glaucoma, prostatic hyperplasia, bladder neck obstruction, or severe renal impairment or urinary retention or any other condition, which, in the opinion of the investigator, would contraindicate the use of an anticholinergic or long-acting beta-agonist agent
- •History of allergy or hypersensitivity to any of the ingredients of study drugs or components of the delivery system
- •Suspected or confirmed SARS-COV2 infection at screening (prior to randomization the subjects will be tested for COVID 19 through rapid antigen test).
- •8.Hospitalization for COPD exacerbation or pneumonia within three months prior to screening.
- •Any subject who experiences pneumonia and/or moderate or severe COPD exacerbation during the run-in period will be excluded.
- •Clinically significant abnormal electrocardiogram (ECG) finding at screening.
- •Lung volume reduction surgery within 12 months prior to the initiation of the study.
- •Requirement of long term (> 12 hours daily) oxygen therapy
- •Unable to stop the following medications at the defined times prior to screening spirometry: Medication Required washout period prior to screening spirometry Ipratropium or ipratropium/salbutamol 8 Hrs combination product Inhaled short acting β-agonists 6 hours Oral β 2-agonists 48 hours Long acting β-agonists (salmeterol and formoterol) or ICS/LABA combination products 48 hours Xanthines 48 hours Cromolyn and nedocromil inhalers 24 hours Zafirlukast, montelukast, zileuton 48 hours Long-acting anticholinergics (Tiotropium etc.) 48 hours Oral or parenteral corticosteroids 6 weeks Any other investigational medication 30 days or 5 half-lives of the investigational drug (whichever is longer) Depot corticosteroids 3 months Inhaled corticosteroids (ICS) Washout not required 13.Currently enrolled in another interventional clinical study or have used any IPs, study drug, or device within 30 days or 5 times the half-life, whichever was longer preceding informed consent or scheduled to participate in another clinical study involving an IP.
- •Additional exclusion criteria for Run-In period: COPD exacerbation requiring treatment with antibiotics, systemic corticosteroids (oral or intravenous), and/or a hospitalization during screening and run-in period.
结局指标
主要结局
•Change from baseline in trough FEV1
时间窗: week 12
次要结局
- 1.Change from baseline in trough FEV1(2. Change from baseline in 2 h post-dose FEV1)
研究者
研究点 (12)
Loading locations...
相似试验
招募中
3 期
Efficacy and safety study to assess between three drugs (Inhaler) in patients with Chronic Obstructive Pulmonary DiseaseCTRI/2023/01/048668Lupin Limited278
已完成
2/3 期
Clinical Study on Lupin’s Ayurvedic Nasal Spray in COVID-19 patients and household contactsCTRI/2021/08/036089Lupin Ltd150
已完成
3 期
Clinical trial to evaluate the efficacy and safety of the fixed dose combination of Tramadol 50 mg IR + Diclofenac 75 mg SR vs fixed dose combination of Tramadol 37.5 mg + Paracetamol 325 mg in treatment of patients with moderate to severe pain due to acute musculoskeletal conditions , acute flare of osteoarthritis , acute flare of rheumatoid arthritis and post operative painCTRI/2011/091/000150Abbott Healthcare Private Limited, Mumbai200
已完成
3 期
A Clinical study to compare the effictiveness and safety of Forb 100 HFA aerosol for inhalation and Foradil Combi set of capsules with inhalation powder in patients with Asthma.CTRI/2017/05/008531RUS Biopharm LLC140
已完成
3 期
A Study to Determine the Efficacy and Safety of Albiglutide as Compared With Liraglutide.Diabetes Mellitus, Type 2CTRI/2010/091/001238GlaxoSmithKline800